CD79A抗体;CD79A Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using *** mouse mAb against Raji (1), Ramos (2), k562 (3), and MOLT4 (4) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using CD79A mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of Raji cells using CD79A mouse mAb (green) and negative control (red).    

  
  

CD79a, a key component of the B-cell receptor (BCR) complex, is encoded by the CD79A gene and pairs with CD79b to form a heterodimer essential for BCR surface expression and signal transduction. As a transmembrane immunoglobulin, CD79a contains an immunoreceptor tyrosine-based activation motif (ITAM) that recruits kinases like Syk upon antigen binding, initiating downstream signaling critical for B-cell development, activation, and differentiation.

CD79a antibodies are valuable tools in research and diagnostics, specifically targeting the invariant CD79a protein expressed exclusively on B-cells. These antibodies enable the identification of B-cell lineages in tissues and blood, aiding in the classification of B-cell malignancies such as chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma. Unlike markers like CD20 or CD19. CD79a retains expression in certain immature B-cell neoplasms and plasma cells, enhancing diagnostic accuracy.

Therapeutically, CD79a has emerged as a potential target for antibody-drug conjugates (ADCs) or bispecific antibodies designed to direct immune cells against malignant B-cells. Recent studies also explore its role in autoimmune diseases, where aberrant BCR signaling contributes to pathology. However, targeting CD79a presents challenges due to its broad expression on healthy B-cells, necessitating precise engineering to balance efficacy and toxicity. Ongoing research continues to refine CD79a antibody applications, bridging gaps in understanding B-cell biology and improving clinical outcomes.